194 related articles for article (PubMed ID: 2011144)
1. Role of genetics and drug metabolism in human cancer risk.
Nebert DW
Mutat Res; 1991 Apr; 247(2):267-81. PubMed ID: 2011144
[TBL] [Abstract][Full Text] [Related]
2. Populations and genetic polymorphisms.
Weber WW
Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics.
Wolf CR; Smith G
Br Med Bull; 1999; 55(2):366-86. PubMed ID: 10723863
[TBL] [Abstract][Full Text] [Related]
4. Genetic control of drug metabolism.
Nebert DW
Adv Exp Med Biol; 1978; 97():55-83. PubMed ID: 347904
[No Abstract] [Full Text] [Related]
5. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
6. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
9. [Interindividual differences in the reaction to drugs and poisons].
Meyer UA
Ther Umsch; 1992 Feb; 49(2):97-101. PubMed ID: 1553631
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
Elfaki I; Mir R; Almutairi FM; Duhier FMA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
Johansson I; Ingelman-Sundberg M
Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and human cancer.
Nebert DW
IARC Sci Publ; 1982; (39):365-80. PubMed ID: 7152614
[TBL] [Abstract][Full Text] [Related]
13. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.
Nebert DW; Ingelman-Sundberg M; Daly AK
Drug Metab Rev; 1999 May; 31(2):467-87. PubMed ID: 10335448
[TBL] [Abstract][Full Text] [Related]
14. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction.
Nebert DW; Puga A; Vasiliou V
Ann N Y Acad Sci; 1993 Jun; 685():624-40. PubMed ID: 8395783
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic drug metabolism.
Relling MV
Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
[TBL] [Abstract][Full Text] [Related]
16. Genetics. SNP-ing drugs to size.
Gura T
Science; 2001 Jul; 293(5530):595. PubMed ID: 11474082
[No Abstract] [Full Text] [Related]
17. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
van Schaik RH
Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
19. Genetic susceptibility to toxic substances and its relationship to carcinogenesis.
Hanke JZ
IARC Sci Publ; 1984; (59):99-106. PubMed ID: 6336235
[TBL] [Abstract][Full Text] [Related]
20. Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.
Morrison A; Levy R
Pharmacogenomics; 2004 Sep; 5(6):673-89. PubMed ID: 15335288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
